CS
TNYA icon

Credit Suisse’s Tenaya Therapeutics TNYA Stock Holding History

Credit Suisse’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$2 – 3702
2022
Q4 		$2 Sell
1
-155
-99% -$378 ﹤0.01% 3901
2022
Q3 		$0 Buy
156
+127
+438% +$593 ﹤0.01% 4291
2022
Q2 		$0 Buy
+29
New +$235 ﹤0.01% 4315

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Credit Suisse's TNYA Position: Q1 2023 in Review

Credit Suisse sold out of Tenaya Therapeutics (TNYA) in Q1 2023, closing a stake of 1 share — an estimated $2 sold.

Credit Suisse first reported a position in TNYA in Q2 2022 and held it in 3 quarters. The position peaked at $2 in Q4 2022. 64 funds tracked by Wall St. Rank hold TNYA as of Q1 2023.

  • Credit Suisse reported no remaining Tenaya Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Tenaya Therapeutics share in Q1 2023, an estimated $2.
  • Credit Suisse first reported a position in Tenaya Therapeutics in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Tenaya Therapeutics position peaked at $2 in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.